 Dr. Chris Schaber Discusses Soligenix HyBryteTM and Thermostabilized VaccinesNew York, New York--Newsfile Corp. - October 13, 2021 - PCG Digital -- In a recent interview with Kristen Kluska, a biotechnology analyst at Cantor, Dr. Chris Schaber, President and CEO of Soligenix NASDAQ: SNGX, spoke about the latest developments with their synthetic hypericin topical treatment HyBryteTM and the Companys ongoing research and development of thermostabilized vaccine candidates for filoviruses and COVID-19. The interview took place at the Cantor Fitzgerald Global Health Care Conference,... 